Compare NUVL & GXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | GXO |
|---|---|---|
| Founded | 2017 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 5.4B |
| IPO Year | 2021 | N/A |
| Metric | NUVL | GXO |
|---|---|---|
| Price | $109.56 | $52.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 12 |
| Target Price | ★ $134.29 | $61.00 |
| AVG Volume (30 Days) | 756.3K | ★ 1.0M |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.76 |
| Revenue | N/A | ★ $12,921,000,000.00 |
| Revenue This Year | N/A | $13.31 |
| Revenue Next Year | N/A | $5.86 |
| P/E Ratio | ★ N/A | $69.03 |
| Revenue Growth | N/A | ★ 16.94 |
| 52 Week Low | $55.54 | $30.46 |
| 52 Week High | $112.88 | $57.99 |
| Indicator | NUVL | GXO |
|---|---|---|
| Relative Strength Index (RSI) | 62.75 | 57.11 |
| Support Level | $103.51 | $50.06 |
| Resistance Level | $112.11 | $52.95 |
| Average True Range (ATR) | 5.16 | 1.38 |
| MACD | -0.24 | 0.57 |
| Stochastic Oscillator | 83.81 | 94.59 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.